Not Only the Left Ventricle: The Impact of Potentially Cardiotoxic Oncological Treatment on the Left Atrium and Right Ventricle
Echocardiography · 2026
DOI: 10.1111/echo.70642 ↗At a glance
Übersichtsarbeit in Echocardiography, 2026. Written by Maria Żak and 3 co-authors. Institution: Students Research Group, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. Major MEDLINE topics: Heart Atria, Cardiotoxicity, Antineoplastic Agents, Heart Ventricles. 26 references.
Abstract (original language)
Background
Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) remain recommended for cardiotoxicity surveillance during cancer therapy, yet it changes late and overlooks injury to the other cardiac chambers.
Purpose
We systematically reviewed echocardiographic and cardiac magnetic resonance (CMR) studies that assessed left atrial (LA), right atrial (RA), and right ventricular (RV) function in patients exposed to potentially cardiotoxic oncological treatment.
Methods
PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials were searched for English‐language studies published between January 2020 and March 2026, following the PRISMA recommendations. Across tumor types—lymphoma, acute lymphoblastic leukemia, breast, gastrointestinal, and melanoma—and across anthracycline‐, trastuzumab‐, fluoropyrimidine‐, and immune checkpoint inhibitor–based regimens, strain imaging detected subclinical dysfunction that conventional measures missed.
Results
LA reservoir strain declined early and frequently preceded any fall in LVEF, outperforming volumetric LA indices for the detection and prediction of cancer therapy–related cardiac dysfunction (CTRCD). RV deformation parameters, particularly free‐wall longitudinal strain and three‐dimensional RV ejection fraction, identified RV involvement that was sometimes independent of LV cardiotoxicity and was associated with adverse cardiac events. Data on the RA remain sparse but point in the same direction.
Conclusion
Multichamber strain assessment adds sensitivity to LVEF and GLS‐based monitoring; standardization of acquisition, reference values, and reporting is needed before it can enter routine cardio‐oncology surveillance.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Students Research Group, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
- First Department of Cardiology and Angiology, Silesian Center for Heart Diseases, Zabrze, Poland.
- Department of Cardiac Surgery, Transplantology and Vascular Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
- Department of Medical Sciences, Collegium Medicum, WSB University, Dąbrowa Górnicza, Poland.
Cite
APA
Żak, M., Suchodolski, A., Niklewski, T., & Szulik, M. (2026). Not Only the Left Ventricle: The Impact of Potentially Cardiotoxic Oncological Treatment on the Left Atrium and Right Ventricle. Echocardiography. https://doi.org/10.1111/echo.70642
Vancouver
Żak M, Suchodolski A, Niklewski T, Szulik M. Not Only the Left Ventricle: The Impact of Potentially Cardiotoxic Oncological Treatment on the Left Atrium and Right Ventricle. Echocardiography. 2026. doi:10.1111/echo.70642
BibTeX
@article{ak2026,
author = {Żak, Maria and Suchodolski, Alexander and Niklewski, Tomasz and Szulik, Mariola},
title = {Not Only the Left Ventricle: The Impact of Potentially Cardiotoxic Oncological Treatment on the Left Atrium and Right Ventricle},
journal = {Echocardiography},
year = {2026},
doi = {10.1111/echo.70642}
}
EUVIMED